Sukhendu Nandi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sukhendu Nandi has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
- Raz Jelinek
Department of Chemistry, Ben Gurion University of the Negev, Beer Sheva 8410501, Israel
17 shared publications Khaja Moinuddin Shaik
Department of Pharmaceutical Analysis National Institute of Pharmaceutical Education and Research (NIPER) Mohali Punjab India
8 shared publicationsPirangi Srikanth
7 shared publicationsRavit Malishev
Department of Chemistry and Ilse Katz Institute for Nanotechnology , Ben-Gurion University of the Negev , Beer-Sheva 84105 , Israel
7 shared publications- Sofiya Kolusheva
Ilse Katz Institute for Nanoscale Science and Technology, Ben-Gurion University of the Negev, Beer Sheva, Israel
7 shared publications Deepak Kumar
6 shared publications
Latest Publications
- 18 September 2026
- Published by Wiley in ChemistrySelect
- Vol. 11 (36)
Unveiling Neuroprotective Effects of a Triazole‐Based Compound in SH‐SY5Y Alzheimer's Disease‐Induced Cell Model
This study presents a novel triazole‐based compound as a highly promising therapeutic agent against Alzheimer's disease (AD), specifically targeting amyloid beta (A β ) toxicity in neuronal cells. Using a comprehensive blend of advanced spectroscopy, microscopy, and mass spectrometry techniques, we demonstrate that this compound effectively inhibits A β peptide oligomerization, a well‐established primary driver of AD pathology. Crucially, high‐resolution mass spectrometry reveals the compound's selective affinity for distinct, highly toxic oligomeric populations, particularly tetramers and pentamers. These specific intermediate structures are abundant during the A β misfolding pathway and play a pivotal role in driving severe neurodegeneration. By disrupting the formation of these early‐stage toxic structures, the compound neutralizes their detrimental effects, limits amyloid accumulation, and actively promotes overall neuronal health. Furthermore, comprehensive molecular modeling analysis identifies acetylcholinesterase (AChE) as the primary macromolecular target for the observed drug action, suggesting a powerful multifaceted mechanism. By successfully mitigating A β ‐induced neurodegeneration and targeting AChE, this research underscores the immense potential of triazole‐based scaffolds in AD drug discovery. Ultimately, these findings highlight the therapeutic value of selectively halting A β oligomerization, offering molecular insights that pave the way for innovative, disease‐modifying treatments.
- 18 September 2026
- Published by Wiley in ChemistrySelect
- Vol. 11 (36)
Unveiling Neuroprotective Effects of a Triazole‐Based Compound in SH‐SY5Y Alzheimer's Disease‐Induced Cell Model
This study presents a novel triazole‐based compound as a highly promising therapeutic agent against Alzheimer's disease (AD), specifically targeting amyloid beta (A β ) toxicity in neuronal cells. Using a comprehensive blend of advanced spectroscopy, microscopy, and mass spectrometry techniques, we demonstrate that this compound effectively inhibits A β peptide oligomerization, a well‐established primary driver of AD pathology. Crucially, high‐resolution mass spectrometry reveals the compound's selective affinity for distinct, highly toxic oligomeric populations, particularly tetramers and pentamers. These specific intermediate structures are abundant during the A β misfolding pathway and play a pivotal role in driving severe neurodegeneration. By disrupting the formation of these early‐stage toxic structures, the compound neutralizes their detrimental effects, limits amyloid accumulation, and actively promotes overall neuronal health. Furthermore, comprehensive molecular modeling analysis identifies acetylcholinesterase (AChE) as the primary macromolecular target for the observed drug action, suggesting a powerful multifaceted mechanism. By successfully mitigating A β ‐induced neurodegeneration and targeting AChE, this research underscores the immense potential of triazole‐based scaffolds in AD drug discovery. Ultimately, these findings highlight the therapeutic value of selectively halting A β oligomerization, offering molecular insights that pave the way for innovative, disease‐modifying treatments.
- Open Access
- 1 April 2026
- Published by KEAI Publishing in Current Pharmaceutical Analysis
- Vol. 22 (3) , 250-261
Wastewater-based epidemiology for monitoring cocaine and cannabis: A review of methods and applications
- 1 April 2026
- Published by KEAI Publishing in Current Pharmaceutical Analysis
- Vol. 22 (3) , 250-261
Open AccessWastewater-based epidemiology for monitoring cocaine and cannabis: A review of methods and applications
- 27 February 2026
- Published by Elsevier in Journal of Chromatography B
- Vol. 1275, 124999
Identification and characterization of atirmociclib metabolites through high resolution-mass spectrometry-based in vitro and in vivo rat biological sample analysis
- 27 February 2026
- Published by Elsevier in Journal of Chromatography B
- Vol. 1275, 124999
Identification and characterization of atirmociclib metabolites through high resolution-mass spectrometry-based in vitro and in vivo rat biological sample analysis
- 10 February 2026
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 26 (11) , 3320-3326
Polydiacetylene (PDA) coated paper-based fluorescence sensor for the detection and quantification of bisphenol
An innovative portable point-of-care device that rapidly and accurately detects and quantifies bisphenol. This sensor ensures quick results, making it an indispensable tool for health and safety monitoring.
- 10 February 2026
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 26 (11) , 3320-3326
Polydiacetylene (PDA) coated paper-based fluorescence sensor for the detection and quantification of bisphenol
An innovative portable point-of-care device that rapidly and accurately detects and quantifies bisphenol. This sensor ensures quick results, making it an indispensable tool for health and safety monitoring.
- 17 October 2025
- Published by Taylor & Francis in Critical Reviews in Analytical Chemistry
- p. 1-31
Real-Time Cell Analysis Using Mass Spectrometry and Nuclear Magnetic Resonance Spectroscopy at Single and Bulk Cellular Levels
Outlining biological processes and disease mechanisms requires a real-time understanding of cellular metabolism. Mass spectrometry (MS) and Nuclear magnetic resonance (NMR) serve as potent analytical methods for metabolomics, leveraging their advantages in the identification and quantification of metabolites. In this review we have discussed MS and NMR based techniques, such as matrix-assisted laser desorption/ionization (MALDI), secondary ionization mass spectrometry (SIMS), desorption electrospray ionization (DESI), direct analysis in real time (DART), and nano electrospray ionization (nano ESI), to develop and implement a MS based technique in its live state for single cell and NMR strategies for thorough, real-time analysis of cell metabolism at bulk cellular level. Single-cell metabolomic investigations using mass spectrometry is a valuable tool for understanding cellular heterogeneity and cell-to-cell variation. However, they can reveal hidden processes and heterogeneity across cells that are often missed by bulk cell analysis. Overcoming the inherently low sensitivity of NMR is crucial for omics studies. This review examines hyperpolarization techniques, including dynamic nuclear polarization (DNP), parahydrogen-induced polarization, sample amplification by reversible exchange (SABER), high-resolution magic angle spinning (HRMAS) NMR, and in vivo magnetic resonance spectroscopy (MRS) for the analysis of live bulk cells. Our discussion encompasses the technological platforms and recent applications of these techniques, utilizing both NMR and MS, along with an overview of metabolomics data analysis tools, such as principal component analysis (PCA) and partial least squares discriminant analysis (PLS-DA).
- 17 October 2025
- Published by Taylor & Francis in Critical Reviews in Analytical Chemistry
- p. 1-31
Real-Time Cell Analysis Using Mass Spectrometry and Nuclear Magnetic Resonance Spectroscopy at Single and Bulk Cellular Levels
Outlining biological processes and disease mechanisms requires a real-time understanding of cellular metabolism. Mass spectrometry (MS) and Nuclear magnetic resonance (NMR) serve as potent analytical methods for metabolomics, leveraging their advantages in the identification and quantification of metabolites. In this review we have discussed MS and NMR based techniques, such as matrix-assisted laser desorption/ionization (MALDI), secondary ionization mass spectrometry (SIMS), desorption electrospray ionization (DESI), direct analysis in real time (DART), and nano electrospray ionization (nano ESI), to develop and implement a MS based technique in its live state for single cell and NMR strategies for thorough, real-time analysis of cell metabolism at bulk cellular level. Single-cell metabolomic investigations using mass spectrometry is a valuable tool for understanding cellular heterogeneity and cell-to-cell variation. However, they can reveal hidden processes and heterogeneity across cells that are often missed by bulk cell analysis. Overcoming the inherently low sensitivity of NMR is crucial for omics studies. This review examines hyperpolarization techniques, including dynamic nuclear polarization (DNP), parahydrogen-induced polarization, sample amplification by reversible exchange (SABER), high-resolution magic angle spinning (HRMAS) NMR, and in vivo magnetic resonance spectroscopy (MRS) for the analysis of live bulk cells. Our discussion encompasses the technological platforms and recent applications of these techniques, utilizing both NMR and MS, along with an overview of metabolomics data analysis tools, such as principal component analysis (PCA) and partial least squares discriminant analysis (PLS-DA).
- 30 August 2025
- Published by Oxford University Press (OUP) in Journal of Chromatographic Science
- Vol. 63 (8)
Simultaneous Bioanalytical Method Development and Validation of Navitoclax and Doxorubicin in Rat Plasma Using UHPLC-HESI-LTQ-MS
A simple, sensitive, and specific liquid chromatography–tandem mass spectrometry (LC–MS/MS) method was successfully developed and validated to determine navitoclax and doxorubicin in rat plasma. Ketoconazole and daunorubicin were employed as internal standards to ensure accurate quantification and method consistency. The sample preparation involved a straightforward protein precipitation technique, which facilitated efficient extraction of the analytes from the plasma matrix. The resulting supernatant was subjected to drying using a vacuum concentrator and later reconstituted before being injected into the LC–MS system. Separation was carried out using a SHIMADZU Shim-pack GIST C-18 column with mobile phase, consisting of a carefully balanced mixture of acetonitrile and water with 0.1% formic acid, with a flow rate of 0.5 mL/min. This composition ensured efficient elution and minimized matrix effects, contributing to the method’s robustness and reproducibility. The developed method was comprehensively validated according to regulatory guidelines, assessing various parameters including specificity, selectivity, sensitivity, calibration curve performance, precision, accuracy, stability and dilution integrity. This bioanalytical method has the potential to be extended to various clinical settings, enabling the monitoring drug metabolism, monitoring potential drug–drug interactions and understanding the pharmacokinetic profile and adverse effect potential of the combination therapy.
- 30 August 2025
- Published by Oxford University Press (OUP) in Journal of Chromatographic Science
- Vol. 63 (8)
Simultaneous Bioanalytical Method Development and Validation of Navitoclax and Doxorubicin in Rat Plasma Using UHPLC-HESI-LTQ-MS
A simple, sensitive, and specific liquid chromatography–tandem mass spectrometry (LC–MS/MS) method was successfully developed and validated to determine navitoclax and doxorubicin in rat plasma. Ketoconazole and daunorubicin were employed as internal standards to ensure accurate quantification and method consistency. The sample preparation involved a straightforward protein precipitation technique, which facilitated efficient extraction of the analytes from the plasma matrix. The resulting supernatant was subjected to drying using a vacuum concentrator and later reconstituted before being injected into the LC–MS system. Separation was carried out using a SHIMADZU Shim-pack GIST C-18 column with mobile phase, consisting of a carefully balanced mixture of acetonitrile and water with 0.1% formic acid, with a flow rate of 0.5 mL/min. This composition ensured efficient elution and minimized matrix effects, contributing to the method’s robustness and reproducibility. The developed method was comprehensively validated according to regulatory guidelines, assessing various parameters including specificity, selectivity, sensitivity, calibration curve performance, precision, accuracy, stability and dilution integrity. This bioanalytical method has the potential to be extended to various clinical settings, enabling the monitoring drug metabolism, monitoring potential drug–drug interactions and understanding the pharmacokinetic profile and adverse effect potential of the combination therapy.
- Open Access
- 19 August 2025
- Published by Royal Society of Chemistry (RSC) in Nanoscale Advances
- Vol. 7 (20) , 6412-6416
Carbon quantum dot-based fluorometric detection of nitrosamine impurities in active pharmaceutical ingredients
A biosensor that uses carbon quantum dots enables precise detection and measurement of nitrosamine impurities, representing a significant advancement in analytical technology for quality control of active pharmaceutical ingredients (APIs).
- 19 August 2025
- Published by Royal Society of Chemistry (RSC) in Nanoscale Advances
- Vol. 7 (20) , 6412-6416
Open AccessCarbon quantum dot-based fluorometric detection of nitrosamine impurities in active pharmaceutical ingredients
A biosensor that uses carbon quantum dots enables precise detection and measurement of nitrosamine impurities, representing a significant advancement in analytical technology for quality control of active pharmaceutical ingredients (APIs).
- Open Access
- 25 March 2025
- Published by Open Exploration Publishing in Exploration of Endocrine and Metabolic Diseases
- Vol. 2, 101425
Significance of FXR agonists in MASLD treatment: a deep dive into lipid alteration by analytical techniques
Metabolic dysfunction-associated steatotic liver disease (MASLD) is rapidly emerging as a global health crisis, affecting over 30% of the population and demanding urgent attention. This redefined condition, previously known as non-alcoholic fatty liver disease (NAFLD), reflects a deeper understanding of the intricate interplay between metabolic dysfunction and liver health. At the heart of MASLD lies the troubling accumulation of triglycerides (TGs) in hepatocytes, which precipitates insulin resistance and oxidative stress, ultimately leading to more severe forms like metabolic dysfunction-associated steatohepatitis (MASH). Excitingly, recent research has spotlighted the farnesoid X receptor (FXR) as a groundbreaking therapeutic target. FXR not only regulates lipid metabolism but also combats inflammation and insulin resistance, making it a potential game-changer in the fight against MASLD. With only one FDA-approved drug, resmetirom, currently available, the exploration of FXR agonists opens new avenues for innovative treatments that could revolutionize patient care. By harnessing the power of FXR to restore metabolic balance and integrating advanced strategies like lipidomics and fatty acid profiling, we stand on the brink of transforming how we approach MASLD and its associated complications, paving the way for a healthier future. This review delves into the promising role of FXR in combating MASLD and its implications for related metabolic disorders, emphasizing the urgency for advanced strategies to detect and manage this burgeoning epidemic.
- 25 March 2025
- Published by Open Exploration Publishing in Exploration of Endocrine and Metabolic Diseases
- Vol. 2, 101425
Open AccessSignificance of FXR agonists in MASLD treatment: a deep dive into lipid alteration by analytical techniques
Metabolic dysfunction-associated steatotic liver disease (MASLD) is rapidly emerging as a global health crisis, affecting over 30% of the population and demanding urgent attention. This redefined condition, previously known as non-alcoholic fatty liver disease (NAFLD), reflects a deeper understanding of the intricate interplay between metabolic dysfunction and liver health. At the heart of MASLD lies the troubling accumulation of triglycerides (TGs) in hepatocytes, which precipitates insulin resistance and oxidative stress, ultimately leading to more severe forms like metabolic dysfunction-associated steatohepatitis (MASH). Excitingly, recent research has spotlighted the farnesoid X receptor (FXR) as a groundbreaking therapeutic target. FXR not only regulates lipid metabolism but also combats inflammation and insulin resistance, making it a potential game-changer in the fight against MASLD. With only one FDA-approved drug, resmetirom, currently available, the exploration of FXR agonists opens new avenues for innovative treatments that could revolutionize patient care. By harnessing the power of FXR to restore metabolic balance and integrating advanced strategies like lipidomics and fatty acid profiling, we stand on the brink of transforming how we approach MASLD and its associated complications, paving the way for a healthier future. This review delves into the promising role of FXR in combating MASLD and its implications for related metabolic disorders, emphasizing the urgency for advanced strategies to detect and manage this burgeoning epidemic.